RESUMEN
Background and Objectives: Community-acquired respiratory virus (CARV) infections pose a serious risk for lung transplant recipients (LTR) as they are prone to severe complications. When the COVID-19 pandemic hit Switzerland in 2020, the government implemented hygiene measures for the general population. We investigated the impact of these measures on the transmission of CARV in lung transplant recipients in Switzerland. Materials and Methods: In this multicenter, retrospective study of lung transplant recipients, we investigated two time periods: the year before the COVID-19 pandemic (1 March 2019-29 February 2020) and the first year of the pandemic (1 March 2020-28 February 2021). Data were mainly collected from the Swiss Transplant Cohort Study (STCS) database. Descriptive statistics were used to analyze the results. Results: Data from 221 Swiss lung transplant cohort patients were evaluated. In the year before the COVID-19 pandemic, 157 infections were diagnosed compared to 71 infections in the first year of the pandemic (decline of 54%, p < 0.001). Influenza virus infections alone showed a remarkable decrease from 17 infections before COVID-19 to 2 infections after the beginning of the pandemic. No significant difference was found in testing behavior; 803 vs. 925 tests were obtained by two of the three centers during the respective periods. Conclusions: We observed a significant decline in CARV infections in the Swiss lung transplant cohort during the first year of the COVID-19 pandemic. These results suggest a relevant impact of hygiene measures when implemented in the population due to the COVID-19 pandemic on the incidence of CARV infections.
Asunto(s)
COVID-19 , SARS-CoV-2 , Humanos , COVID-19/epidemiología , Receptores de Trasplantes , Suiza/epidemiología , Estudios de Cohortes , Pandemias , Estudios Retrospectivos , Higiene , PulmónRESUMEN
Epidemiological studies have shown an increased respiratory morbidity and mortality as a consequence of exposure to air pollution. Short term exposure to air pollution is associated with an increased respiratory mortality and exacerbation of respiratory symptoms. Long term exposure to air pollution is associated with a progressive lung function decline as well as the development of chronic pulmonary diseases. In this article, we analyze the impact of major atmospheric pollutants on respiratory health and its impact on COPD, asthma and lung cancer. This review explores the impact of household air pollution on respiratory health as well as the relationship between ambient atmospheric air pollution and physical activity.
De nombreuses études épidémiologiques ont montré une augmentation de la morbidité et de la mortalité liées au système respiratoire en relation avec la pollution. L'exposition aux polluants atmosphériques provoque des effets à court terme, suite à une exposition à un pic de pollution, et des effets à long termeâ : déclin de la fonction pulmonaire et développement de pathologies chroniques. Cet article explore l'impact des différents polluants atmosphériques sur la BPCO, l'asthme ainsi que le cancer pulmonaire. Les conséquences de la pollution domestique sur le système respiratoire ainsi que l'impact de la pollution atmosphérique sur l'effort physique seront également abordés.
Asunto(s)
Contaminantes Atmosféricos , Contaminación del Aire , Asma , Enfermedades Pulmonares , Contaminantes Atmosféricos/toxicidad , Contaminación del Aire/efectos adversos , Asma/epidemiología , Exposición a Riesgos Ambientales , Humanos , Sistema Respiratorio/químicaRESUMEN
Solid organ transplant (SOT) candidates may not be immune against potentially vaccine-preventable diseases because of insufficient immunizations and/or limited vaccine responses. We evaluated the impact on vaccine immunity at transplant of a systematic vaccinology workup at listing that included (1) pneumococcal with and without influenza immunization, (2) serology-based vaccine recommendations against measles, varicella, hepatitis B virus, hepatitis A virus, and tetanus, and (3) the documentation of vaccines and serology tests in a national electronic immunization registry (www.myvaccines.ch). Among 219 SOT candidates assessed between January 2014 and November 2015, 54 patients were transplanted during the study. Between listing and transplant, catch-up immunizations increased the patients' immunity from 70% to 87% (hepatitis A virus, P = .008), from 22% to 41% (hepatitis B virus, P = .008), from 77% to 91% (tetanus, P = .03), and from 78% to 98% (Streptococcus pneumoniae, P = .002). Their immunity at transplant was significantly higher against S. pneumoniae (P = .006) and slightly higher against hepatitis A virus (P = .07), but not against hepatitis B virus, than that of 65 SOT recipients transplanted in 2013. This demonstrates the value of a systematic multimodal serology-based approach of immunizations of SOT candidates at listing and the need for optimized strategies to increase their hepatitis B virus vaccine responses.
Asunto(s)
Inmunización/estadística & datos numéricos , Trasplante de Órganos/métodos , Inmunología del Trasplante/inmunología , Vacunación/estadística & datos numéricos , Vacunas Virales/inmunología , Adulto , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Pronóstico , Vacunas Virales/clasificaciónRESUMEN
Screening for latent tuberculosis infection (LTI) is recommended in immunosuppressed patients due to an increased risk of progression from LTI to active tuberculosis. Screening involves indirect immunological tests such as the tuberculin skin test (TST) and the interferon-y release assays (IGRAs). IGRAs seem to show superior performance compared to TST in screening for LTI. However, their use and interpretation in immunosuppressed patients is questionable, particularly because of an increased number of false negative or indeterminate results and a low agreement between tests. Presently, there are no swiss national recommendations for their use in immunosuppressed -patients, except for candidates to anti-TNF treatment.
Le dépistage d'une infection tuberculeuse latente (ITL) est recommandé chez les patients immunosupprimés en raison du risque accru de la progression de l'ITL vers la tuberculose active. Son dépistage se fait notamment à l'aide de tests immunologiques indirects que sont le test de sensibilité à la tuberculine (TST) et les tests de détection de production de l'interféron-gamma (IGRA). Les IGRA semblent montrer une performance supérieure par rapport au TST dans le dépistage d'une ITL. Mais leur utilisation et leur interprétation chez les immunosupprimés sont sujettes à caution notamment à cause d'un nombre accru de résultats faussement négatifs ou indéterminés et d'une mauvaise concordance entre tests. À l'heure actuelle, il n'existe pas de recommandations nationales suisses sur leur utilisation chez les immunosupprimés mis à part pour les candidats au traitement anti-TNF (tumor necrosis factor).
Asunto(s)
Huésped Inmunocomprometido , Síndromes de Inmunodeficiencia/complicaciones , Síndromes de Inmunodeficiencia/microbiología , Tuberculosis Latente/complicaciones , Tuberculosis Latente/diagnóstico , Humanos , Ensayos de Liberación de Interferón gamma , Sensibilidad y Especificidad , Prueba de Tuberculina , Factor de Necrosis Tumoral alfa/antagonistas & inhibidoresRESUMEN
BACKGROUND: Airway stenting (AS) commenced in Europe circa 1987 with the first placement of a dedicated silicone airway stent. Subsequently, over the last 3 decades, AS was spread throughout Europe, using different insertion techniques and different types of stents. OBJECTIVES: This study is an international survey conducted by the European Association of Bronchology and Interventional Pulmonology (EABIP) focusing on AS practice within 26 European countries. METHODS: A questionnaire was sent to all EABIP National Delegates in February 2015. National delegates were responsible for obtaining precise and objective data regarding the current AS practice in their country. The deadline for data collection was February 2016. RESULTS: France, Germany, and the UK are the 3 leading countries in terms of number of centres performing AS. These 3 nations represent the highest ranked nations within Europe in terms of gross national income. Overall, pulmonologists perform AS exclusively in 5 countries and predominately in 12. AS is performed almost exclusively in public hospitals. AS performed under general anaesthesia is the rule for the majority of institutions, and local anaesthesia is an alternative in 9 countries. Rigid bronchoscopy techniques are predominant in 20 countries. Amongst commercially available stents, both Dumon and Ultraflex are by far the most commonly deployed. Finally, 11 countries reported that AS is an economically viable activity, while 10 claimed that it is not. CONCLUSION: This EABIP survey demonstrates that there is significant heterogeneity in AS practice within Europe. Therapeutic bronchoscopy training and economic issues/reimbursement for procedures are likely to be the primary reasons explaining these findings.
Asunto(s)
Broncoscopía/estadística & datos numéricos , Neumología/estadística & datos numéricos , Stents/estadística & datos numéricos , Broncoscopía/instrumentación , Europa (Continente) , Humanos , Neumología/instrumentación , Neumología/métodos , Neumología/organización & administración , Encuestas y CuestionariosRESUMEN
Previous research has shown that the built environment plays a crucial role for health-related quality of life (HRQoL) and health care utilization. But, there is limited evidence on the independence of this association from lifestyle and social environment. The objective of this cross-sectional study was to investigate these associations, independent of the social environment, physical activity and body mass index (BMI). We used data from the third follow-up of the Swiss study on Air Pollution and Lung and Heart diseases In Adults (SAPALDIA), a population based cohort with associated biobank. Covariate adjusted multiple quantile and polytomous logistic regressions were performed to test associations of variables describing the perceived built environment with HRQoL and health care utilization. Higher HRQoL and less health care utilization were associated with less reported transportation noise annoyance. Higher HRQoL was also associated with greater satisfaction with the living environment and more perceived access to greenspaces. These results were independent of the social environment (living alone and social engagement) and lifestyle (physical activity level and BMI). This study provides further evidence that the built environment should be designed to integrate living and green spaces but separate living and traffic spaces in order to improve health and wellbeing and potentially save health care costs.
Asunto(s)
Entorno Construido/psicología , Aceptación de la Atención de Salud/estadística & datos numéricos , Calidad de Vida , Adulto , Contaminación del Aire/efectos adversos , Contaminación del Aire/estadística & datos numéricos , Índice de Masa Corporal , Estudios Transversales , Ejercicio Físico , Femenino , Humanos , Masculino , Persona de Mediana Edad , Aceptación de la Atención de Salud/psicología , Calidad de Vida/psicología , Medio Social , SuizaRESUMEN
Among recent technological progress, electromagnetic navigational bronchoscopy (ENB), based on the principle of "GPS", allows the bronchoscopist to reach parenchymal lesions situated beyond the field of regular bronchoscopy. Compared to CT-scan guided transthoracic needle aspiration, the yield is lower (65%). However, the rate of complication (pneumothorax, hemorrhage) is significantly lower and the patient is not irradiated. Moreover, the yield remains stable also for cases associated to a lower yield of the transthoracic approach (small and/or deep and/or benign lesion). Beyond the diagnosis of peripheral lung nodules, ENB (alone or in combination with endobronchial ultrasound) is also an efficient and safe tool for disease staging by simultaneous (during the same procedure) sampling of associated hypermetabolic lymph nodes.
Asunto(s)
Broncoscopía/métodos , Neoplasias Pulmonares/diagnóstico , Nódulo Pulmonar Solitario/diagnóstico , Biopsia con Aguja/métodos , Broncoscopios , Fenómenos Electromagnéticos , Diseño de Equipo , Humanos , Neoplasias Pulmonares/patología , Nódulo Pulmonar Solitario/patología , Tomografía Computarizada por Rayos XRESUMEN
The effects of lung afferents denervation on cardiovascular regulation can be assessed on bilateral lung transplantation patients. The high-frequency component of heart rate variability is known to be synchronous with breathing frequency. Then, if heart beat is neurally modulated by breathing frequency, we may expect disappearance of high frequency of heart rate variability in bilateral lung transplantation patients. On 11 patients and 11 matching healthy controls, we measured R-R interval (electrocardiography), blood pressure (Portapres® ) and breathing frequency (ultrasonic device) in supine rest, during 10-min free breathing, 10-min cadenced breathing (0·25 Hz) and 5-min handgrip. We analysed heart rate variability and spontaneous variability of arterial blood pressure, by power spectral analysis, and baroreflex sensitivity, by the sequence method. Concerning heart rate variability, with respect to controls, transplant recipients had lower total power and lower low- and high-frequency power. The low-frequency/high-frequency ratio was higher. Concerning systolic, diastolic and mean arterial pressure variability, transplant recipients had lower total power (only for cadenced breathing), low frequency and low-frequency/high-frequency ratio during free and cadenced breathing. Baroreflex sensitivity was decreased. Denervated lungs induced strong heart rate variability reduction. The higher low-frequency/high-frequency ratio suggested that the total power drop was mostly due to high frequency. These results support the hypothesis that neural modulation from lung afferents contributes to the high frequency of heart rate variability.
Asunto(s)
Desnervación Autonómica , Sistema Nervioso Autónomo/cirugía , Barorreflejo , Frecuencia Cardíaca , Corazón/inervación , Trasplante de Pulmón/métodos , Adulto , Anciano , Presión Arterial , Sistema Nervioso Autónomo/fisiopatología , Estudios de Casos y Controles , Electrocardiografía , Femenino , Fuerza de la Mano , Humanos , Masculino , Persona de Mediana Edad , Contracción Muscular , Frecuencia Respiratoria , Factores de Tiempo , Resultado del TratamientoRESUMEN
OBJECTIVE: Lung transplantation has evolved from an experimental procedure to a viable therapeutic option in many countries. In Switzerland, the first lung transplant was performed in November 1992, more than ten years after the first successful procedure world-wide. Thenceforward, a prospective national lung transplant registry was established, principally to enable quality control. PATIENTS: The data of all patients transplanted in the two Swiss Lung Transplant centres Zurich University Hospital and Centre de Romandie (Geneva-Lausanne) were analysed. RESULTS: In 10 years 242 lung transplants have been performed. Underlying lung diseases were cystic fibrosis including bronchiectasis (32%), emphysema (32%), parenchymal disorders (19%), pulmonary hypertension (11%) and lymphangioleiomyomatosis (3%). There were only 3% redo procedures. The 1, 5 and 9 year survival rates were 77% (95% CI 72-82), 64% (95% CI 57-71) and 56% (95% CI 45-67), respectively. The 5 year survival rate of patients transplanted since 1998 was 72% (95% CI 64-80). Multivariate Cox regression analysis revealed that survival was significantly better in this group compared to those transplanted before 1998 (HR 0.44, 0.26-0.75). Patients aged 60 years and older (HR 5.67, 95% CI 2.50-12.89) and those with pulmonary hypertension (HR 2.01, 95% CI 1.10-3.65) had a significantly worse prognosis The most frequent causes of death were infections (29%), bronchiolitis obliterans syndrome (25%) and multiple organ failure (14%). CONCLUSION: The 10-year Swiss experience of lung transplantation compares favourably with the international data. The best results are obtained in cystic fibrosis, pulmonary emphysema and parenchymal disorders.
Asunto(s)
Trasplante de Pulmón/mortalidad , Trasplante de Pulmón/estadística & datos numéricos , Sistema de Registros , Adolescente , Adulto , Factores de Edad , Anciano , Causas de Muerte , Niño , Femenino , Humanos , Hipertensión Pulmonar/complicaciones , Enfermedades Pulmonares/cirugía , Masculino , Persona de Mediana Edad , Análisis Multivariante , Estudios Prospectivos , Reoperación/estadística & datos numéricos , Tasa de Supervivencia , Suiza/epidemiologíaRESUMEN
BACKGROUND: Respiratory syncytial virus (RSV) infections in lung transplant recipients (LTRs) have been associated with significant morbidity and mortality. Immunoglobulins, ribavirin, and palivizumab are suggested treatments for both pre-emptive and therapeutic purposes. However, in the absence of randomized, placebo-controlled trials, efficacy is controversial and there is toxicity as well as cost concerns. METHODS: We retrospectively reviewed cases of lower respiratory tract RSV infections in adult LTRs. Diagnosis was based on clinical history, combined with a positive polymerase chain reaction (PCR) and/or viral cultures of bronchoalveolar lavage (BAL) specimens. RESULTS: Ten symptomatic patients were identified (7 men and 3 women, age range 28 to 64 years). All were hospitalized for community-acquired respiratory tract infections. Two patients had a concomitant acute Grade A3 graft rejection, and 1 patient had a concomitant bacterial pneumonia. Eight patients did not receive a specific anti-RSV treatment because of clinical stability and/or improvement at the time of RSV diagnosis. Only 2 patients (1 with Grade A3 allograft rejection and 1 requiring mechanical ventilation) received ribavirin and palivizumab. All patients recovered without complications and with no persistent RSV infection. However, bronchiolitis obliterans (BOS) staging worsened in 6 patients during the mean follow-up of 45 months. CONCLUSIONS: Our data suggest that mild RSV infections in LTRs might evolve favorably in the absence of specific anti-viral therapy. However, this observation needs confirmation in a large clinical trial specifically investigating the development of BOS in untreated vs treated patients.
Asunto(s)
Enfermedades Pulmonares/cirugía , Trasplante de Pulmón , Complicaciones Posoperatorias/epidemiología , Infecciones por Virus Sincitial Respiratorio/epidemiología , Índice de Severidad de la Enfermedad , Adulto , Antivirales/uso terapéutico , Líquido del Lavado Bronquioalveolar/virología , Femenino , Volumen Espiratorio Forzado/fisiología , Humanos , Incidencia , Pulmón/virología , Masculino , Persona de Mediana Edad , Complicaciones Posoperatorias/tratamiento farmacológico , Complicaciones Posoperatorias/virología , Infecciones por Virus Sincitial Respiratorio/tratamiento farmacológico , Infecciones por Virus Sincitial Respiratorio/fisiopatología , Virus Sincitiales Respiratorios/aislamiento & purificación , Estudios RetrospectivosRESUMEN
There have been few reports of neuroendocrine proliferation and tumors developing after transplantation. We report the first two of such cases encountered after lung transplantation and review the literature on these rare tumors after solid-organ transplantation. In the general population, these are indolent and rare tumors, as opposed to neuroendocrine carcinoma, and their behavior is unknown in transplant recipients.